Emerald Holding Appoints Glenn Kerkhof as Interim CEO Amid Leadership Transition
- Emerald Clinical Trials appoints Glenn Kerkhof as Interim CEO following Mary Gunn's departure, effective July 30, 2025.
- Kerkhof aims to maintain stability and uphold service standards during the leadership transition at Emerald Clinical Trials.
- The organization continues to serve over 100 biotech firms and six of the top ten pharmaceutical companies globally.
Emerald Clinical Trials Navigates Leadership Transition with Experienced Interim CEO
Emerald Clinical Trials, a premier clinical research organization headquartered in Singapore, undergoes a significant leadership transition as Mary Gunn steps down as CEO. Effective July 30, 2025, the Board appoints Glenn Kerkhof, a seasoned executive with over 30 years of experience in the clinical research field, as the Interim CEO. This strategic decision comes at a critical moment as the organization embarks on a search for a permanent successor. Kerkhof, who has been a long-standing member of the Board, is known for his previous roles as CEO of Chiltern and Executive Chairman of George Clinical, both positions that have equipped him with extensive knowledge and insight into the clinical trial landscape.
In his new role, Kerkhof is tasked with maintaining stability and momentum during the transition period. Sean Carney, Chair of the Board, expresses gratitude for Gunn's contributions while emphasizing confidence in Kerkhof's capability to ensure that client services remain uninterrupted. He highlights the organization’s robust therapeutic focus, scientific depth, and strong partnerships with clients as key strengths that will help navigate this transitional phase. By leveraging these attributes, Kerkhof aims to uphold the high standards of service delivery that Emerald Clinical Trials is known for, ensuring that it continues to meet the needs of its extensive clientele.
Emerald Clinical Trials serves a diverse group of clients, including over 100 biotech firms and six of the top ten pharmaceutical companies globally. The company provides comprehensive clinical trial services across all phases of research, which underscores its critical role in the pharmaceutical and biotechnology sectors. Kerkhof’s commitment to supporting global teams while delivering effective solutions positions Emerald Clinical Trials well for future success, even amidst changes in leadership. As the organization looks towards the future, its operational expertise and dedication to scientific excellence remain central to its mission.
In addition to organizational changes, Emerald Clinical Trials continues to focus on enhancing its service offerings and client relationships. The leadership transition presents an opportunity for the company to reassess its strategic goals and reinforce its commitment to innovation in clinical research. As the search for a new permanent CEO progresses, Kerkhof’s leadership is expected to provide continuity and reassurance to clients and stakeholders alike.
For further details about Emerald Clinical Trials and its comprehensive services, interested parties can visit the official website at www.emeraldclinical.com.